Can we further define patient groups who benefit from immunotherapy in advanced NSCLC?
Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups
Refining patient selection for atezolizumab in resected NSCLC
Results from an exploratory analysis of the IMpower010 trial confirm that there is a correlation between tumour-cell PD-L1 expression and disease-free survival
Tumour mutational burden as a number – is it predictive enough?
Data suggest that assessing the quality as well as the quantity of tumour mutations may enhance prediction of outcomes in patients treated with immune checkpoint inhibitors
New immunotherapies are explored to improve the treatment of solid tumours
From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed
Trained immunity: a new promising oncology target?
In-depth understanding of immunological cellular mechanisms provides the basis to explore new ways to modulate the immune system for more effective treatment of cancer
Developing immunotherapies for mesothelioma
Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation
Survival benefits of pembrolizumab plus chemotherapy are confirmed in East-Asian patients with advanced NSCLC
Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status
Immunotherapy: from initial scepticism to the heart of cancer treatment
The ESMO Award for Immuno-Oncology 2021 is given to Prof. Wolf H. Fridman, whose research has made significant contributions to unveiling the prognostic and predictive role of the tumour microenvironment
How much is enough with immunotherapy?
For the recipient of the ESMO Award for Immuno-Oncology 2020, Dr Jedd Wolchok, one of the biggest challenges in the field is knowing how and when to de-escalate immunotherapy
A step closer to determining the best sequential approach for treatment of BRAF-mutated metastatic melanoma?
Data from SECOMBIT provide useful insights to the optimal sequence of immune checkpoint inhibitor therapy and targeted treatment combinations for patients with BRAF-mutated, advanced melanoma